Koninklijke Philips NV ADR
NYSE: PHG · HEALTHCARE · MEDICAL DEVICES
Updated 2026-04-29
Koninklijke Philips NV ADR (PHG) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for PHG.
Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.
PHG historical valuation range
Where current P/E sits in PHG's own 5Y range.
PHG intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
PHG valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
Current: 23.47x
P/S Ratio — History
Current: 1.36x
Is PHG overvalued in 2026?
Koninklijke Philips NV ADR (PHG) currently trades at $25.58 per share with a market capitalization of $24,333,971,000.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 49/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
The stock trades at a P/E ratio of 23.5x, below its 5-year median of 25.8x. The PEG ratio of 0.36 suggests earnings growth is outpacing the multiple, a classic sign of undervaluation.
Looking at its own history, PHG is currently trading cheaper than 67% of the last 5Y on P/E. This places it in the 33th percentile of its historical range, a reasonable but unremarkable position.
Our discounted cash flow model estimates PHG's intrinsic value at $33.33 per share, against the current market price of $25.58. This implies a margin of safety of +3.78%. The stock is priced close to its estimated fair value, offering limited upside without further operational improvement.
The Piotroski F-Score of 6/9 puts financial quality in a middling range, neither a standout strength nor an obvious red flag.
Bottom line: PHG appears richly valued on our framework, with a Smart Value Score of 49/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.
Frequently asked questions
Is PHG overvalued in 2026?
Based on a Smart Value Score of 49/100, PHG appears overvalued. Current price exceeds what fundamentals currently justify.
What is PHG's fair value?
Our DCF model estimates PHG's intrinsic value at $33.33 per share, versus the current price of $25.58. This produces a margin of safety of +3.78%.
What P/E ratio does PHG trade at?
PHG trades at a P/E of 23.5x on trailing twelve-month earnings, compared to its 5-year median of 25.8x.
Is PHG a buy based on valuation?
WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 49/100 reflects the combined read on growth, quality, and price. The profile skews cautious. Consider waiting for a better price or clearer operational improvement.
How does PHG's valuation compare to its history?
On P/E, PHG currently sits in the 33th percentile of its own 5Y range. That is below its long-run median relative to where it has traded over the period.
What is PHG's Smart Value Score?
PHG's Smart Value Score is 49/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.